{
    "nct_id": "NCT04648254",
    "official_title": "A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion At the RP2D in Patients with Advanced Solid Tumors",
    "inclusion_criteria": "* Patients with histologically or cytologically confirmed advanced or metastatic solid tumors, that have progressed following standard of care therapy or for which there is no standard therapy which confers clinical benefit\n* Measurable disease per RECIST v 1.1\n* ECOG performance status 0 or 1\n* Life expectancy of at least 3 months\n* Age â‰¥ 18 years\n* Signed, written IRB-approved informed consent form\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months\n* Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec (females) and >450 msec (males)\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n* Active, poorly controlled autoimmune or inflammatory diseases",
    "miscellaneous_criteria": ""
}